intetumumab

Drug Overview

Intetumumab (often referred to in research by its laboratory name, CNTO 95) is a highly specialized, experimental medication. It belongs to a group of advanced medicines known as monoclonal antibodies. These are “Smart Drugs” designed to find, attach to, and attack specific parts of cancer cells without harming healthy tissue in the way traditional treatments might.

• Generic Name: Intetumumab
• US Brand Names: None. Because it is an experimental medication, it does not yet have a commercial brand name.
• Drug Class: Monoclonal Antibody / Targeted Therapy / Integrin Antagonist
• Route of Administration: Intravenous (IV) Infusion (delivered directly into a vein)
• FDA Approval Status: Investigational. Intetumumab is not currently approved by the US Food and Drug Administration (FDA) for standard public use. It is only available to patients who are actively enrolled in approved clinical trials.
  
  Read about intetumumab and its immunotherapy potential. Our hospital’s research-driven team offers personalized, advanced clinical care.

What Is It and How Does It Work? (Mechanism of Action)

To understand intetumumab, it helps to understand how a cancer cell behaves. Imagine a cancer cell as a weed. For a weed to grow and spread, it needs to plant its roots firmly into the soil and pull in water. Cancer cells do something very similar. They use proteins called integrins as their “roots” or “Velcro” to anchor themselves into healthy surrounding tissue. Once anchored, they send out chemical signals to build a brand new blood supply, a process known as angiogenesis.

Intetumumab is a Targeted Therapy designed to act like a chemical shield against these roots. Specifically, it targets a family of proteins called alpha-V (αV) integrins.

Here is how intetumumab works at the molecular level:

• Finding the Target: After being infused into the bloodstream, intetumumab acts like a homing missile. It travels through the body until it finds and binds directly to the alpha-V integrins on the surface of tumor cells and nearby blood vessel cells.
• Blocking the Connection: Once attached, it physically blocks the integrin receptors from grabbing onto the “extracellular matrix.” This matrix is the supportive web of proteins surrounding human cells, containing sticky molecules like vitronectin and fibronectin.
• Stopping Cell Growth: Because the cancer cell can no longer anchor itself, a critical internal communication line called the FAK/ERK/AKT signaling pathway is silenced. This pathway normally tells the cell to survive and divide. Without these instructions, the cancer cell’s growth cycle comes to a hard stop.
• Triggering Cell Death: Deprived of its anchoring and survival signals, the cancer cell activates its own self-destruct sequence. This natural process of programmed cell death is called apoptosis.
• Starving the Tumor: By blocking integrins on blood vessel cells, intetumumab also stops the creation of new blood vessels. This starves the tumor of the oxygen and nutrients it desperately needs to survive.

FDA-Approved Clinical Indications

Because intetumumab is an investigational agent, it does not currently have official FDA-approved indications for routine, everyday clinical practice. However, it has been widely studied in controlled clinical trials for the following purposes:

• Oncological Uses (In Clinical Trials):
  • Prostate Cancer: Evaluated in patients with advanced castration-resistant prostate cancer, often combined with standard chemotherapy.
  • Non-Small Cell Lung Cancer (NSCLC): Researched for its ability to stop lung tumors from growing and spreading to other organs.
  • Melanoma: Tested in advanced forms of skin cancer.
  • Solid Tumors: Studied generally in advanced solid tumors that have failed to respond to other conventional treatments.
• Non-oncological Uses:
  • Currently, there are no non-oncological uses for this medication. It is strictly being researched for cancer care.

Dosage and Administration Protocols

Because intetumumab is an experimental drug, healthcare providers administer it based on strict clinical trial guidelines. The exact dose is carefully calculated based on the patient’s body weight and the specific rules of the research study.

Clinical Efficacy and Research Results

In the landscape of modern oncology, researchers rely on strict numerical data to see if a new drug outperforms older ones. Recent reviews of clinical trial data (2020–2025) have provided a clear picture of intetumumab’s efficacy. While early laboratory tests showed it was highly effective at shrinking tumors in animal models, translating these results to human patients proved challenging.

• Prostate Cancer Outcomes: In a major clinical trial involving patients with metastatic castration-resistant prostate cancer, doctors tested what would happen if they added intetumumab to a standard chemotherapy drug called docetaxel. They measured “progression-free survival,” which is the amount of time a patient lives without the disease getting worse. The results showed that adding intetumumab did not improve survival. Patients receiving only the standard chemotherapy had a progression-free survival of about 11.0 months. However, patients receiving the combination of chemotherapy and intetumumab had an inferior progression-free survival of roughly 7.6 months.
• Lung Cancer and Melanoma: Similar human trials in other cancers did not show a massive improvement in overall disease progression compared to existing treatments.

Because the combination did not consistently improve overall survival rates, large-scale trials for certain cancers were halted. Today, scientists are using this valuable data to understand how tumors develop resistance. They are actively researching if “Smart Drugs” like intetumumab can be redesigned as delivery vehicles to carry toxic payloads directly into cancer cells, rather than acting alone.

Safety Profile and Side Effects

Like all powerful cancer medications, intetumumab can cause side effects. Because it does not have FDA approval, there is no official Black Box Warning for this drug. However, clinical trial teams monitor patients very closely for any adverse reactions.

Common Side Effects (>10%)

• Fatigue: Feeling a deep sense of tiredness or lack of energy that does not improve with sleep.
• Gastrointestinal Distress: Many patients experience mild to moderate nausea, occasional vomiting, diarrhea, or constipation.
• Infusion-Related Reactions: Some patients may experience mild chills, a low fever, skin redness, or a rash while the IV is dripping.

Serious Adverse Events

• Neutropenia: A severe drop in white blood cells. This dramatically weakens the immune system and makes it harder for the body to fight off routine infections.
• Bleeding Risks: Because the drug aggressively affects blood vessel growth, there is a risk of unexpected internal or external bleeding.
• Poor Wound Healing: The body may struggle to heal cuts or surgical incisions while the drug is in the system.

Management Strategies

• For Fatigue: Rest often. Taking light, short daily walks can actually help keep energy levels steady.
• For Nausea: The medical team will usually provide strong anti-nausea medicines before the IV infusion begins.
• For Infection Risk (Neutropenia): Wash your hands frequently and avoid crowds. If you develop a fever higher than 100.4°F (38°C), it is considered a medical emergency, and you must call your doctor right away.
• For Healing Issues: Doctors will temporarily stop the drug several weeks before any planned surgery or dental work to ensure your body can heal normally.

Research Areas

While intetumumab isn’t a mainstay in regenerative medicine, it’s pivotal in immunotherapy. Targeting integrins may dismantle the tumor’s protective microenvironment, enabling T-cells to infiltrate and destroy cancer more effectively.

Patient Management and Practical Recommendations

Patient safety is the top priority during any clinical trial. If you are participating in a study using intetumumab, your healthcare team will require strict adherence to safety guidelines.

Pre-treatment Tests to be Performed

• Blood Tests: A Complete Blood Count (CBC) to check white blood cells, and comprehensive metabolic panels to ensure your liver and kidneys are functioning properly.
• Pregnancy Test: A negative blood pregnancy test is strictly required for women of childbearing age before treatment begins, as this drug can cause severe harm to an unborn baby.
• Cardiovascular Checks: Because it affects blood vessels, your doctor will check your baseline blood pressure and overall heart health.

Precautions During Treatment

• Wound Care: Tell your doctor immediately if you have any cuts, scrapes, or sores that are not healing normally.
• Medical Procedures: Inform all your doctors and dentists that you are on an experimental anti-angiogenesis drug before any dental work or surgical procedure.
• Infection Control: Practice strict hygiene to protect your potentially weakened immune system.

“Do’s and Don’ts” List

• DO drink plenty of water to stay hydrated before and after your IV infusion.
• DO keep a daily journal of how you feel, noting any side effects, and share it with your trial nurse.
• DO use reliable, highly effective birth control during treatment and for several months after your last dose.
• DON’T take blood thinners, aspirin, or ibuprofen without asking your doctor first, as these can drastically increase bleeding risks.
• DON’T engage in high-risk sports or activities where you could easily cut or injure yourself.
• DON’T receive any live vaccines while taking this medication.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Intetumumab is an investigational therapeutic agent and is not currently approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for general clinical use. It is available only through participation in approved, controlled clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, potential risks, and your eligibility for clinical trials.